{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:17:20Z","timestamp":1753888640068,"version":"3.41.2"},"reference-count":35,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Background: Monoclonal antibodies have proven efficacy in the management of several conditions and infliximab (IFX) is one of the most important drugs of the class. Some recent data have shown low rates of both persistence and adherence to several available biologics.  Objective: The objective of this study was to describe adherence and persistence rate to IFX treatment and also persistence in the patient support program (PSP), among patients diagnosed with inflammatory bowel diseases (IBD) or rheumatic diseases (RD) enrolled in the program of a large pharmaceutical company in Brazil.  Methods: Retrospective observational analysis using the PSP database. IBD or RD patients using IFX enrolled on the PSP database between September 2015 and August 2019 were retrospectively evaluated to identify the persistence rate and adherence and followed up until March 1, 2020. Patients were excluded if treatment start date was prior to program entry; first infusion prior to September 1st, 2015 or after August 31st, 2019; the patients did not started treatment; and patients with \u201cOTHERS\u201d in \u201cIndication\u201d field. Persistence was assessed considering both persistence in the program (\u201cPSP persistence\u201d) and persistence on IFX in the PSP (\u201cIFX persistence in the PSP\u201d). PSP persistence was defined as the proportion of patients remaining in the program at 6, 12, 24, 36 and 48 months after initiating IFX. To determine IFX persistence in the PSP, censoring was defined at the time the patient left the program, died, or was lost to follow-up. Adherence to treatment was measured by medication possession ratio ((MPR) - All days supply \/ elapsed days from first prescription to last day of medication possession)). Descriptive statistics were initially used. Kaplan-Meier curve, the median time estimated by the survival function, Cox regression model, and restricted mean survival time (RMST) were used to evaluate the treatment persistence time at 24 months and the logistic regression model was performed aiming to identify variables associated with adherence (MPR \u226580%).  Results: A total of 10,233 patients were analyzed, 5,826 (56.9%) with the diagnosis of RD and 4,407 (43.1%) of IBD. At the end of the follow-up (median 9.1 months from PSP entry to the last infusion), persistence in the PSP was 65.6%, 48.2%, 31.0%, 20.7% and 13.1% at 6, 12, 24, 36 and 48 months, respectively. Considering persistence on IFX in the PSP, estimates were 93.7%, 87.8%, 77.0%, 62.4% and 53.0% at 6, 12, 24, 36 and 48 months, respectively. Variables associated with the risk of non-persistence were gender, country region and diagnosis of rheumatoid arthritis and ankylosing spondylitis. Median MPR was 94.2%, while the percentage of patients with MPR \u226580% was 91.0%. Variables associated with MPR\u226580% were country region and diagnosis of Crohn\u2019s disease.  Conclusion: Many patients leave the program without discontinuing IFX, since the 12-month persistence were very different between program and medication estimates, while high adherence rates were observed among patients enrolled in the PSP. Data highlights the benefits of a PSP.<\/jats:p>","DOI":"10.1590\/s0004-2803.24612023-149","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T10:38:48Z","timestamp":1716201528000},"source":"Crossref","is-referenced-by-count":0,"title":["ADHERENCE AND PERSISTENCE TO TREATMENT WITH INFLIXIMAB: ANALYSIS OF A PATIENT SUPPORT PROGRAM COHORT IN BRAZIL"],"prefix":"10.1590","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4797-4892","authenticated-orcid":false,"given":"Aniela Bonorino Xexeo Castelo","family":"BRANCO","sequence":"first","affiliation":[{"name":"Janssen Cilag Ltda,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-0849","authenticated-orcid":false,"given":"Wilton","family":"ARGOLO","sequence":"additional","affiliation":[{"name":"Janssen Cilag Ltda,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4406-7285","authenticated-orcid":false,"given":"Nathalia","family":"SANTOS","sequence":"additional","affiliation":[{"name":"Janssen Cilag Ltda,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-8118","authenticated-orcid":false,"given":"Gabriela","family":"HERNANDEZ","sequence":"additional","affiliation":[{"name":"Janssen Cilag Ltda,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-7493","authenticated-orcid":false,"given":"Adriana","family":"KAKEHASI","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4486-9894","authenticated-orcid":false,"given":"Carlos Walter","family":"SOBRADO","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8378-5186","authenticated-orcid":false,"given":"Richard","family":"MELSHEIMER","sequence":"additional","affiliation":[{"name":"Janssen Global Services LLC,  United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref1","first-page":"3","article-title":"Immune-mediated diseases: where do we stand?","volume":"601","author":"Shurin MR","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"ref2","first-page":"9","article-title":"Use of Biologics and Biosimilars in Rheumatology","volume":"65","author":"Sharma SK","year":"2017","journal-title":"J Assoc Physicians India"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/jcp.2005.032300","article-title":"Biologic therapies: What and when?","volume":"60","author":"Johnston SL","year":"2007","journal-title":"J Clin Pathol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer SB","year":"2002","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis","volume":"353","author":"Rutgeerts P","year":"2005","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial","volume":"50","author":"St. Clair EW","year":"2004","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun J","year":"2002","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni C","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich K","year":"2005","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/ibd\/izab346","article-title":"Geosocial Features and Loss of Biodiversity Underlie Variable Rates of Inflammatory Bowel Disease in a Large Developing Country: A Population-Based Study","volume":"28","author":"da Luz Moreira A","year":"2022","journal-title":"Inflamm Bowel Dis"},{"series-title":"Doen\u00e7as reum\u00e1ticas","key":"ref11"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5114\/reum.2016.60216","article-title":"Social implications of rheumatic diseases","volume":"2","author":"K\u0142ak A","year":"2016","journal-title":"Rheumatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2147\/PPA.S140457","article-title":"Medication adherence has an impact on disease activity in rheumatoid arthritis: a systematic review and meta-analysis","volume":"11","author":"Li L","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication Compliance and Persistence: Terminology and Definitions","volume":"11","author":"Cramer JA","year":"2008","journal-title":"Value Heal"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2147\/PPA.S167508","article-title":"Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: A systematic literature review","volume":"12","author":"Murage MJ","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546634.2018.1479725","article-title":"Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity","volume":"30","author":"Murage MJ","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2020.625755","article-title":"Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis","volume":"7","author":"Mourad AI","year":"2021","journal-title":"Front Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: Treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen C","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027059","article-title":"Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: A retrospective study","volume":"9","author":"Alvarez-Madrazo S","year":"2019","journal-title":"BMJ Open"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/s10620-019-05867-1","article-title":"Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study","volume":"65","author":"Jung YS","year":"2020","journal-title":"Dig Dis Sci"},{"key":"ref21","first-page":"SP338","article-title":"Cost of biologic treatment persistence or switching in rheumatoid arthritis","volume":"24","author":"Gu T","year":"2018","journal-title":"Am J Manag Care"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000519123","article-title":"Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use","volume":"6","author":"Bargo D","year":"2021","journal-title":"Inflamm Intest Dis"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016982","article-title":"Economic impact of medication non-adherence by disease groups: a systematic review","volume":"8","author":"Cutler RL","year":"2018","journal-title":"BMJ Open"},{"key":"ref24","first-page":"859","article-title":"Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis","volume":"23","author":"Rubin DT","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.3748\/wjg.v19.i27.4344","article-title":"Low rates of adherence for tumor necrosis factor-\u03b1 inhibitors in Crohn\u2019s disease and rheumatoid arthritis: Results of a systematic review","volume":"19","author":"Fidder HH","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"8","key":"ref26","article-title":"2017 Impact of a patient support program on adherence and cost - Humira","volume":"23","author":"Rubin DT","year":"2017","journal-title":"AbbVie"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12325-018-0706-0","article-title":"Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study.","volume":"35","author":"Srulovici E","year":"2018","journal-title":"Adv Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/17512433.2019.1586533","article-title":"First line of biological drugs in rheumatoid arthritis: a medication persistence analysis","volume":"12","author":"dos Santos JBR","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref29","first-page":"1086","article-title":"Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit","volume":"27","author":"Fendrick AM","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"series-title":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA)","key":"ref30"},{"series-title":"Parcerias para o Desenvolvimento Produtivo","key":"ref31"},{"series-title":"Portaria SAES\/MS no 140. 2022.","key":"ref32","first-page":"180"},{"key":"ref33","first-page":"1","article-title":"Factors associated with low adherence to medicine treatment for chronic diseases in brazil","volume":"50","author":"Tavares NUL","year":"2016","journal-title":"Rev Saude Publica"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/5269493","article-title":"Adherence to Medical Treatment in Inflammatory Bowel Disease Patients from a Referral Center in Bahia-Brazil","volume":"2020","author":"Andrade LD","year":"2020","journal-title":"Biomed Res Int"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2147\/PPA.S215037","article-title":"Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population","volume":"13","author":"Brixner D","year":"2019","journal-title":"Patient Prefer Adherence"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["Ades\u00e3o e persist\u00eancia ao tratamento com infliximabe: an\u00e1lise de uma coorte de um programa de suporte ao paciente no Brasil"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032024000100606&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T10:39:16Z","timestamp":1716201556000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032024000100606&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":35,"alternative-id":["S0004-28032024000100606"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.24612023-149","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"type":"electronic","value":"1678-4219"},{"type":"print","value":"0004-2803"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e23149"}}